Which treatment is not considered first-line in acute COPD/asthma exacerbations according to the material?

Which treatment is not considered first-line in acute COPD/asthma exacerbations according to the material?

• A. Magnesium sulfate
• B. Short-acting beta-agonist
• C. Corticosteroids
• D. Oxygen therapy

Answer: (A)

In acute COPD or asthma exacerbations, the priorities are to rapidly relieve bronchospasm, reduce airway inflammation, and maintain adequate oxygenation. The first-line actions are a fast-acting bronchodilator to open the airways (short-acting beta-agonist), systemic corticosteroids to curb inflammation and shorten recovery, and supplemental oxygen to keep oxygen levels safe. Magnesium sulfate is not started as a routine first-line therapy; it’s an adjunct used in severe or life-threatening cases when patients do not fully respond to initial treatment, providing extra bronchodilation. So the treatment not considered first-line is magnesium sulfate.

In acute COPD or asthma exacerbations, the priorities are to rapidly relieve bronchospasm, reduce airway inflammation, and maintain adequate oxygenation. The first-line actions are a fast-acting bronchodilator to open the airways (short-acting beta-agonist), systemic corticosteroids to curb inflammation and shorten recovery, and supplemental oxygen to keep oxygen levels safe. Magnesium sulfate is not started as a routine first-line therapy; it’s an adjunct used in severe or life-threatening cases when patients do not fully respond to initial treatment, providing extra bronchodilation. So the treatment not considered first-line is magnesium sulfate.